Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)Defense World · 3 days ago
Entrada Therapeutics Appoints Linea Aspesi as Chief People OfficerGlobeNewsWire · 3 days ago
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyGlobeNewsWire · Oct 14, 2026
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45GlobeNewsWire · Oct 14, 2026
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying OpportunitySeeking Alpha · Oct 10, 2026
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant ProgramGlobeNewsWire · Sep 10, 2026Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$1.05 | -$1.01 | Beat |
| May 7, 2026 | -$1.06 | -$0.95 | Beat |
| Feb 26, 2026 | -$1.32 | -$0.94 | Beat |
| Nov 6, 2025 | -$1.04 | -$1.06 | Miss |
| Aug 6, 2025 | -$0.86 | -$1.04 | Miss |
| May 8, 2025 | -$0.78 | -$0.42 | Beat |